183 related articles for article (PubMed ID: 26052595)
1. Molecular biomarkers in gastric cancer.
Elimova E; Wadhwa R; Shiozaki H; Sudo K; Estrella JS; Badgwell BD; Das P; Matamoros A; Song S; Ajani JA
J Natl Compr Canc Netw; 2015 Apr; 13(4):e19-29. PubMed ID: 26052595
[TBL] [Abstract][Full Text] [Related]
2. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.
Riquelme I; Saavedra K; Espinoza JA; Weber H; García P; Nervi B; Garrido M; Corvalán AH; Roa JC; Bizama C
Oncotarget; 2015 Sep; 6(28):24750-79. PubMed ID: 26267324
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.
Carlomagno N; Incollingo P; Tammaro V; Peluso G; Rupealta N; Chiacchio G; Sandoval Sotelo ML; Minieri G; Pisani A; Riccio E; Sabbatini M; Bracale UM; Calogero A; Dodaro CA; Santangelo M
Biomed Res Int; 2017; 2017():7869802. PubMed ID: 29094049
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
Young K; Chau I
Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
7. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic analysis suggests that UGT2B15 activates the Hippo‑YAP signaling pathway leading to the pathogenesis of gastric cancer.
Chen X; Li D; Wang N; Yang M; Liao A; Wang S; Hu G; Zeng B; Yao Y; Liu D; Liu H; Zhou W; Xiao W; Li P; Ming C; Ping S; Chen P; Jing L; Bai Y; Yao J
Oncol Rep; 2018 Oct; 40(4):1855-1862. PubMed ID: 30066917
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.
Kim HK; Green JE
Pharmacogenomics; 2014 Feb; 15(3):375-84. PubMed ID: 24533716
[TBL] [Abstract][Full Text] [Related]
10. Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling.
Zhang J; Wang G; Chu SJ; Zhu JS; Zhang R; Lu WW; Xia LQ; Lu YM; Da W; Sun Q
Oncotarget; 2016 Mar; 7(13):16180-93. PubMed ID: 26921249
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
12. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N
J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer.
Zhang J; Yang YC; Zhu JS; Zhou Z; Chen WX
Int J Immunopathol Pharmacol; 2012; 25(4):977-87. PubMed ID: 23298488
[TBL] [Abstract][Full Text] [Related]
14. Innovative personalized medicine in gastric cancer: time to move forward.
Lee J; Kim KM; Kang WK; Ou SH
Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
[TBL] [Abstract][Full Text] [Related]
15. Signaling pathways and therapeutic interventions in gastric cancer.
Lei ZN; Teng QX; Tian Q; Chen W; Xie Y; Wu K; Zeng Q; Zeng L; Pan Y; Chen ZS; He Y
Signal Transduct Target Ther; 2022 Oct; 7(1):358. PubMed ID: 36209270
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
17. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
Cheung DY; Kim JK
Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
[TBL] [Abstract][Full Text] [Related]
18. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
19. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
